Company news

ClearPoint Neuro Inc. news in 2024

ClearPoint Neuro Inc.'s news releases, calls and decks from 2024, newest first.

View company

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

November 12, 2024

ClearPoint Neuro Reports Third Quarter 2024 Results

November 6, 2024

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

October 30, 2024

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

October 16, 2024

ClearPoint Neuro Announces Early Repayment of $10 Million Note

August 25, 2024

ClearPoint Neuro Reports Second Quarter 2024 Results

August 6, 2024

ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

July 16, 2024

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

June 19, 2024

ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

May 31, 2024

ClearPoint Neuro Reports First Quarter 2024 Results

May 6, 2024

ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore

May 1, 2024

ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory

April 28, 2024

ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

April 23, 2024

ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

April 22, 2024

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

April 15, 2024

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

March 18, 2024

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

March 11, 2024

Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System

March 10, 2024

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

February 29, 2024

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

February 28, 2024

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

February 27, 2024

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

February 20, 2024

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

January 23, 2024

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

January 21, 2024

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

January 15, 2024

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

January 7, 2024

Calls in 2024

Decks in 2024